5,120 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by First Western Trust Bank

First Western Trust Bank acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 5,120 shares of the medical research company’s stock, valued at approximately $390,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth about $34,000. Operose Advisors LLC increased its holdings in Edwards Lifesciences by 247.0% during the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after purchasing an additional 452 shares during the last quarter. SRS Capital Advisors Inc. raised its position in shares of Edwards Lifesciences by 292.6% in the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 474 shares in the last quarter. NBC Securities Inc. purchased a new position in shares of Edwards Lifesciences during the 3rd quarter valued at approximately $52,000. Finally, ORG Partners LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter worth approximately $66,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the sale, the vice president now owns 173,849 shares of the company’s stock, valued at $14,639,824.29. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total value of $1,212,624.00. Following the completion of the sale, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $14,639,824.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 857 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $85.60, for a total transaction of $73,359.20. Following the completion of the transaction, the vice president now directly owns 23,890 shares in the company, valued at approximately $2,044,984. The disclosure for this sale can be found here. Insiders sold 231,550 shares of company stock worth $20,384,302 in the last 90 days. Corporate insiders own 1.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Oppenheimer increased their price objective on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Monday, April 29th. Stifel Nicolaus lifted their target price on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Friday, April 26th. Royal Bank of Canada upped their price target on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Finally, Wells Fargo & Company boosted their target price on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $93.27.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded up $2.33 during trading hours on Thursday, hitting $87.42. The stock had a trading volume of 3,421,899 shares, compared to its average volume of 3,709,712. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The stock’s fifty day simple moving average is $90.03 and its 200 day simple moving average is $79.73. The firm has a market capitalization of $52.68 billion, a price-to-earnings ratio of 37.68, a PEG ratio of 3.59 and a beta of 1.10. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.